Leah Croll, MD, Assistant Professor of Clinical Neurology at the Lewis Katz School of Medicine at Temple University, offered perspective to ABC NewsOne about lecanemab, an experimental drug that in newly published data from a large, late-stage clinical trial has been shown to slow the rate of cognitive decline in early stage Alzheimer’s disease. The FDA still needs to approve the drug.
800-TEMPLE-MED
Schedule Appointment
SEARCH TEMPLE HEALTH